No Significant Effects of IL-23 on Initiating and Perpetuating the Axial Spondyloarthritis: The Reasons for the Failure of IL-23 Inhibitors [PDF]
Frontiers in Immunology, 2022 Axial spondyloarthritis (axSpA) is comprised of ankylosing spondylitis (AS) and non-radiographic axSpA. In recent years, the involvement of the interleukin (IL)-23/IL-17 axis in the pathophysiology of axSpA has been widely proposed.
Hua Zhang, Han-Lei Jiang, Sheng-Ming Dai
doaj +5 more sources
Short-term risk and long-term incidence rate of infection and malignancy with IL-17 and IL-23 inhibitors in adult patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis [PDF]
Frontiers in Immunology, 2023 The risk of infection and malignancy may be a concern for patients with psoriasis receiving interleukin (IL)-17 and IL-23 inhibitors, particularly with long-term treatments.
Shuwei Wu +10 more
doaj +3 more sources
The Role of IL-23 Inhibitors in Crohn's Disease. [PDF]
J Clin Med, 2023 Promoting a Th17 pathogenic response, the interleukin (IL)-23 pathway is crucial in the pathophysiology of inflammatory bowel disease (IBD). With a favorable safety profile, ustekinumab, a monoclonal antibody targeting the shared p40 component of IL-12 ...
Fanizza J +11 more
europepmc +5 more sources
Clinical benefits and complication profile of IL-23 inhibitors in patients with psoriatic arthritis: a systematic review and meta-analysis [PDF]
Frontiers in PharmacologyBackgroundPsoriatic arthritis (PsA) is a chronic inflammatory disease with heterogeneous manifestations affecting both joints and skin. Interleukin-23 (IL-23) plays a central role in the Th17-mediated inflammatory pathway implicated in PsA pathogenesis ...
Jingxin Zeng +10 more
doaj +4 more sources
MASLD and liver fibrosis in patients with psoriasis receiving IL-17 or IL-23 inhibitors: a systematic review [PDF]
Therapeutic Advances in GastroenterologyBackground: Metabolic dysfunction-associated steatotic liver disease (MASLD) is more prevalent in patients with psoriasis compared to healthy individuals.
José González Fernández +3 more
doaj +3 more sources
Emerging Therapies for Palmoplantar Pustulosis with a Focus on IL-23 Inhibitors. [PDF]
J Clin MedPalmoplantar pustulosis (PPP) is a chronic inflammatory skin disease characterized by recurrent pustules, erythema, and scaling on the palms and soles, leading to a significantly reduced quality of life.
Nam KH, Kim YS.
europepmc +4 more sources
Comparative Effects of IL-17 and IL-23 Inhibitors on Lipid Profiles and Lipid-Derived Atherogenic Indices in Patients with Psoriasis [PDF]
PharmaceuticalsBackground: Psoriasis is associated with increased cardiovascular risk and altered lipid metabolism. The comparative effects of IL-17 and IL-23 inhibitors on lipid-derived atherogenic indices remain unclear. Objective: To compare the effects of IL-17 and
Candan Celik +2 more
doaj +2 more sources
Efficacy and safety of IL-17, IL-12/23, and IL-23 inhibitors for psoriatic arthritis: a network meta-analysis of randomized controlled trials [PDF]
Frontiers in ImmunologyBackgroundPsoriatic arthritis (PsA) is a chronic inflammatory disease that impacts both the skin and joints. Currently, interleukin (IL)-17, IL-12/23, and IL-23 inhibitors have become integral components of PsA treatment regimens.
Shan Gao +3 more
doaj +2 more sources
Comparative efficacy and safety of IL-17 and IL-23 inhibitors for moderate-to-severe psoriasis in Asian populations: a systematic review and meta-analysis [PDF]
BMC ImmunologyBackground Psoriasis is a chronic inflammatory skin disorder affecting a significant portion of the global population. Biologics targeting the IL-17 and IL-23 pathways are effective in treating moderate-to-severe psoriasis; however, most clinical trials ...
Mohammad Alzghool +2 more
doaj +2 more sources
Differentiating IL-23 Inhibitors in Crohn’s Disease
DrugsInterleukin-23 (IL-23), a member of the IL-12 family of cytokines, plays a critical role in intestinal homeostasis and inflammation and is strongly implicated in the pathogenesis of inflammatory bowel disease (IBD). Therapies targeting the p19 subunit of
Nardone, Olga Maria +4 more
core +4 more sources